Lung Cancer

An Inhaled Vaccine Could Potentially Help Mesothelioma Patients in the Future

April 16, 2021
Categories: , , , ,

An inhaled vaccine could be used for mesothelioma treatment soon. Research done at MIT is showing that the inhaled vaccine can trigger an immune response for certain infections and possibly lung-based cancers. This is great news for people with mesothelioma. Lung infections typically start on mucosal membranes, so researchers created a vaccine that can bind…

Cholesterol Drugs Called Statins Could Help Extend Mesothelioma Sufferers’ Lives

December 18, 2020
Categories: , , , ,

A group of drugs called statins used for controlling cholesterol are showing that they can help mesothelioma patients taking PD-1 inhibitors survive longer. Researchers in Italy and the Netherlands found this information in an international study of 250 patients. The patients studied either had pleural mesothelioma or non-small cell lung cancer. The researchers found that…

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

November 6, 2020
Categories: , ,

Primary Outcome Measures safety of PB103 [ Time Frame: one year ] assessment of adverse events Secondary Outcome Measures efficacy of PB103 [ Time Frame: one year ] assessment of Progression Free Survival, PFS Inclusion Criteria Recipient: Recipients (Subjects) are between 20-70 years of age. Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥ 4/8 match at HLA-A, -B,…

Keytruda and Tumor Treating Fields Combination Could Soon be Used for Mesothelioma

August 28, 2020
Categories: , , , , ,

A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding within the PD-1 pathway. It…

Genetically Modified T-Cells for the Treatment of Mesothelioma and Other Tumors

August 14, 2020
Categories: , , , ,

Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage is best for treating people.…

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

July 31, 2020
Categories: , , , ,

Primary Outcome Measures Primary endpoint for cohort 1: Objective response rate (ORR) according to RECIST 1.1 [ Time Frame: At the date of tumor assessment according to RECIST 1.1, assessed up to 2 years after registration ] ORR according to RECIST 1.1 is defined as the proportion of patients, whose best overall response is either complete response (CR) or…

Halofuginone Could Soon be Used to Treat Mesothelioma

June 4, 2020
Categories: , , , , , ,

Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can potentially help extend their lives.…

Upcoming Mesothelioma Events in 2020

December 27, 2019
Categories: , , , , ,

If you are interested in learning more about mesothelioma, we have a curated list of different events coming up in 2020. If you live near or are able to travel to these events, they can help you and your loved ones understand the disease better. Mayo Clinic Radiation Oncology: Current Practice and Future Direction This…

Lung Cancer Awareness Month Starts Today

November 1, 2019
Categories:

Today starts Lung Cancer Awareness Month. In November, we come together to recognize this deadly cancer and learn about different causes and treatments. Knowing the different statistics and causes could help save a lot of people’s lives. Lung cancer is the leading cause of death due to cancer in men and women. In 2018, it…

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

April 26, 2019
Categories: , , ,

The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.